Superior efficacy and similar safety of double dose anakinra in Erdheim-Chester disease after single dose treatment-Reference-Cited by-同舟云学术

Superior efficacy and similar safety of double dose anakinra in Erdheim-Chester disease after single dose treatment

Published:2018-03-15 Issue: Volume: Page:e1450712
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Franconieri Fréderic¹,Deshayes Samuel¹^ORCID,de Boysson Hubert¹,Trad Salim²^ORCID,Martin Silva Nicolas¹,Terrier Benjamin³,Bienvenu Boris¹,Galateau-Sallé Françoise⁴,Emile Jean-François⁵,Johnson Alison C.⁶^ORCID,Aouba Achille¹

Affiliation:

1. CHU de Caen, Department of Internal Medicine and Clinical Immunology, Caen, F-14000, France

2. CHU Ambroise Paré – Université Paris Ouest, Department of Internal Medicine, Boulogne-Billancourt, France

3. Hôpital Cochin, Department of Internal Medicine, Paris, France

4. National referent center MESOPATH-Base National Clinicobiologic Databasis MESOBANK Register multicenter MESONAT-Sante public cancer center of Léon Bérard, Department of Biopathology, Lyon, France

5. Department of Pathology, Ambroise Paré Hospital & EA4340, Versailles, Boulogne, France

6. François Baclesse Cancer Center, Department of Oncology, Caen, France

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2018.1450712

Reference35 articles.

1. Erdheim–Chester disease

2. Erdheim-Chester Disease: a comprehensive review of the literature

3. Erdheim–Chester disease: A systematic review